Review of Priapism Litigation in the United States.
Journal
Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
10
12
2020
revised:
20
04
2021
accepted:
02
05
2021
pubmed:
17
5
2021
medline:
10
2
2022
entrez:
16
5
2021
Statut:
ppublish
Résumé
To review medical malpractice trends and to identify the most common claims filed against medical providers for the management of patients with priapism. Using the Westlaw legal database, a search was done for the keyword "priapism" between July 1, 1980 and July 1, 2020. Cases were evaluated for plaintiff demographics, reasons for filing claims, management outcomes, legal verdicts and awards and further categorized based upon the timing of the alleged malpractice. Alleged negligence during the pre-management period was cited in 30 cases. Administration of psychotropic medications was the most common reasons for filing pre-management claims 22/56 (39.3%). Delay in care accounted for 18/56 (32.1%) and complications of surgery were 5/56 (8.9%) of claims. The majority of the completed cases were in favor of the defendants (39/47; 83.0%). There was no association between type of health care provider or timing of alleged malpractice and ultimate verdict. Prescribing psychoactive medications without warning of the adverse effect profile is the most common reason for claims filed against providers with trazodone as the leading medication. Medical providers should ensure that patients are well informed of this adverse effect prior to prescription. Regardless, the majority of medical malpractice cases carry a verdict in favor of the defendant.
Identifiants
pubmed: 33992665
pii: S0090-4295(21)00391-5
doi: 10.1016/j.urology.2021.05.001
pii:
doi:
Substances chimiques
Psychotropic Drugs
0
Trazodone
YBK48BXK30
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-172Informations de copyright
Copyright © 2021. Published by Elsevier Inc.